Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men

Garland CF, Garland FC (1980) Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 9(3):227–231 Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10(5A):1307–1311 Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132(5):1952–1960 Peehl DM et al (1994) Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54(3):805–810 Oades GM et al (2002) Vitamin D receptor-dependent antitumour effects of 1, 25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90(6):607–616 Getzenberg RH et al (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50(6):999–1006 Schwartz GG et al (1995) 1, 25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46(3):365–369 Schwartz GG et al (1994) Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14(3A):1077–1081 Ahonen MH et al (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11(9):847–852 Corder EH et al (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2(5):467–472 Li H et al (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103 Tuohimaa P et al (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108(1):104–108 Ahn J et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100(11):796–804 Braun MM et al (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6(3):235–239 Faupel-Badger JM et al (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16(12):2784–2786 Gann PH et al (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5(2):121–126 Jacobs ET et al (2004) Plasma levels of 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537 Platz EA et al (2004) Plasma 1, 25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255–265 Nomura AM et al (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425–432 Tretli S et al (2009) Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 100(3):450–454 Travis RC et al (2009) Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European prospective investigation into cancer and nutrition (EPIC). Am J Epidemiol 169(10):1223–1232 Orwoll E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study–a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26(5):569–585 Washburn RA et al (1993) The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol 46(2):153–162 Orwoll E et al (2009) Vitamin D deficiency in older men. J Clin Endocrinol Metab 94(4):1214–1222 Barlow WE et al (1999) Analysis of case-cohort designs. J Clin Epidemiol 52(12):1165–1172 Singh RJ et al (2006) C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab 91(8):3055–3061 Prentice RL (1986) A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73(1):1–11 Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70(12):2861–2869 Schwartz GG, Hanchette CL (2006) UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 17(8):1091–1101 Grant WB (2002) An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer 94(6):1867–1875 Luscombe CJ et al (2001) Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 358(9282):641–642 John EM et al (2005) Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 65(12):5470–5479 Bodiwala D et al (2003) Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 24(4):711–717 Lagunova Z et al (2007) Prostate cancer survival is dependent on season of diagnosis. Prostate 67(12):1362–1370 Robsahm TE et al (2004) Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 15(2):149–158 Zhou W et al (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14(10):2303–2309 Hedlund TE, Moffatt KA, Miller GJ (1996) Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58(3):277–288 Miller GJ et al (1992) The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 52(3):515–520 Beer TM et al (2004) Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13(12):2225–2232 Chen TC et al (2003) Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 88(2):315–322 Schwartz GG et al (1998) Human prostate cells synthesize 1, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7(5):391–395 Hsu JY et al (2001) Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61(7):2852–2856 Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700 Zehnder D et al (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86(2):888–894 Hewison M et al (2000) 1 alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 25(2):141–148 Giovannucci E et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98(7):451–459 Sakr WA, Partin AW (2001) Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 57(4 Suppl 1):115–120